|| Checking for direct PDF access through Ovid
The human attenuated rotavirus vaccine, Rotarix (GlaxoSmithKline Biologicals, Rixensart, Belgium), is now licensed in more than 100 countries, including Europe. Because of the diversity of circulating rotavirus types worldwide, the potential impact of this vaccine should be evaluated by geographic context according to regional rotavirus type distribution.The potential vaccine efficacy (VE) of Rotarix against severe rotavirus gastroenteritis (RVGE) was calculated using a simple modeling approach considering different published rotavirus type distributions and known type-specific VE.Utilizing global rotavirus type distribution data and type-specific VE data from a large recent European Phase III study, the potential proportion of severe RVGE cases averted by 2 oral doses of Rotarix was found to range from 89.1% (in Africa) to 94.5% (in Europe). Based on a more conservative approach using type-specific VE data from a large Latin American Phase III study, the potential proportion of severe RVGE cases averted by Rotarix was found to range from 83.2% to 88.1%. In Europe, utilizing most recent rotavirus type distribution data from 2 prospective surveillance studies in areas where the G9 type is currently prevalent, 2 oral doses of Rotarix could potentially avert between 85.1% (based on Latin American type-specific VE data) and 95.5% (based on European type-specific VE data) of all cases of severe RVGE among children aged <5 years.Despite geographic and temporal differences in type distribution, the potential impact of Rotarix is expected to be high in all continents, including those with emerging rotavirus types.